BGNE vs. BMRN, VTRS, SRPT, ALNY, UTHR, RDY, TEVA, GMAB, CTLT, and ROIV
Should you be buying BeiGene stock or one of its competitors? The main competitors of BeiGene include BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Catalent (CTLT), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
BeiGene (NASDAQ:BGNE) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.
BeiGene has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.
BioMarin Pharmaceutical has lower revenue, but higher earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
BioMarin Pharmaceutical received 995 more outperform votes than BeiGene when rated by MarketBeat users. Likewise, 74.70% of users gave BioMarin Pharmaceutical an outperform vote while only 69.14% of users gave BeiGene an outperform vote.
In the previous week, BioMarin Pharmaceutical had 24 more articles in the media than BeiGene. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 10 mentions for BeiGene. BeiGene's average media sentiment score of 0.94 beat BioMarin Pharmaceutical's score of 0.27 indicating that BeiGene is being referred to more favorably in the media.
BioMarin Pharmaceutical has a net margin of 8.31% compared to BeiGene's net margin of -28.39%. BioMarin Pharmaceutical's return on equity of 5.34% beat BeiGene's return on equity.
BeiGene currently has a consensus price target of $251.93, suggesting a potential upside of 45.75%. BioMarin Pharmaceutical has a consensus price target of $106.11, suggesting a potential upside of 36.80%. Given BeiGene's stronger consensus rating and higher possible upside, research analysts plainly believe BeiGene is more favorable than BioMarin Pharmaceutical.
48.5% of BeiGene shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 7.4% of BeiGene shares are owned by company insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
BioMarin Pharmaceutical beats BeiGene on 12 of the 18 factors compared between the two stocks.
Get BeiGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
